Non-hormonal male contraceptive YCT-529 has cleared the first human clinical trial. "Sixteen healthy men received either placebo or escalating single doses of YCT-529 to assess its safety and tolerability. YCT-529 was well tolerated, and no adverse effects were noted. The positive results from this first clinical trial laid the groundwork for a second trial," researchers said.